Muro, Shigeo http://orcid.org/0000-0001-7452-9191
Suzuki, Masaru
Nakamura, Shuhei
Wang, Jocelyn Ruoyi
Garry, Elizabeth M.
Sakamoto, Wataru
de Souza, Sabrina
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Received: 28 January 2021
Accepted: 10 June 2021
First Online: 17 June 2021
Declarations
:
: The study was conducted in accordance with the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects and a protocol that was approved by an Independent Ethics Committee (Japan Conference of Clinical Research). Patient informed consent was not required because the study used retrospective de-identified data.
: Not applicable.
: SM has received lecture fees from Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca, GlaxoSmithKline, and Novartis. MS has received research funding from Nippon Boehringer Ingelheim Co., Ltd. and Novartis, and lecture fees from Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca, GlaxoSmithKline, and Novartis. JRW was an employee and with stock options at Aetion Inc. at the time the study was conducted and now has equity. EMG is an employee and holds stock options at Aetion Inc. Aetion was funded by Nippon Boehringer Ingelheim Co., Ltd. to collect the data and conduct the analyses. SN and WS are employees of Nippon Boehringer Ingelheim Co., Ltd. SdS is an employee of Boehringer Ingelheim International GmbH.